[HTML][HTML] Fc-engineered therapeutic antibodies: recent advances and future directions
DT Abdeldaim, K Schindowski - Pharmaceutics, 2023 - mdpi.com
Monoclonal therapeutic antibodies have revolutionized the treatment of cancer and other
diseases. Fc engineering aims to enhance the effector functions or half-life of therapeutic …
diseases. Fc engineering aims to enhance the effector functions or half-life of therapeutic …
[HTML][HTML] A general Fc engineering platform for the next generation of antibody therapeutics
D Chen, Y Zhao, M Li, H Shang, N Li, F Li, W Wang… - Theranostics, 2021 - ncbi.nlm.nih.gov
Rationale: Fc engineering has become the focus of antibody drug development. The current
mutagenesis and in silico protein design methods are confined by the limited throughput …
mutagenesis and in silico protein design methods are confined by the limited throughput …
Optimizing therapeutic antibody function: progress with Fc domain engineering
E Kaneko, R Niwa - BioDrugs, 2011 - Springer
Since the establishment of monoclonal antibody production using hybridoma technology in
the mid-1970s, there has been expanding progress and continuous technological …
the mid-1970s, there has been expanding progress and continuous technological …
Advances in the assessment and control of the effector functions of therapeutic antibodies
XR Jiang, A Song, S Bergelson, T Arroll… - Nature reviews Drug …, 2011 - nature.com
The Fc (crystallizable fragment) region of therapeutic antibodies can have an important role
in their safety and efficacy. Although much is known about the structure–activity relationship …
in their safety and efficacy. Although much is known about the structure–activity relationship …
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
F Mimoto, T Igawa, T Kuramochi, H Katada, S Kadono… - MAbs, 2013 - Taylor & Francis
Fc engineering is a promising approach to enhance the antitumor efficacy of monoclonal
antibodies (mAbs) through antibody-dependent cell-mediated cytotoxicity (ADCC). Glyco …
antibodies (mAbs) through antibody-dependent cell-mediated cytotoxicity (ADCC). Glyco …
Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs
AM Chenoweth, BD Wines, JC Anania… - … and Cell Biology, 2020 - Wiley Online Library
The human fragment crystallizable (Fc) γ receptor (R) interacts with antigen‐complexed
immunoglobulin (Ig) G ligands to both activate and modulate a powerful network of …
immunoglobulin (Ig) G ligands to both activate and modulate a powerful network of …
An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations
O Vafa, GL Gilliland, RJ Brezski, B Strake, T Wilkinson… - Methods, 2014 - Elsevier
Abstract The Fc variant of IgG2, designated as IgG2σ, was engineered with
V234A/G237A/P238S/H268A/V309L/A330S/P331S substitutions to eliminate affinity for Fcγ …
V234A/G237A/P238S/H268A/V309L/A330S/P331S substitutions to eliminate affinity for Fcγ …
[HTML][HTML] Soluble monomeric IgG1 Fc
T Ying, W Chen, R Gong, Y Feng… - Journal of Biological …, 2012 - ASBMB
Antibody fragments are emerging as promising biopharmaceuticals because of their
relatively small size and other unique properties. However, compared with full-size …
relatively small size and other unique properties. However, compared with full-size …
Modulation of antibody effector function
JR Desjarlais, GA Lazar - Experimental cell research, 2011 - Elsevier
Several novel technologies have evolved over the last decade for the modification of
antibodies to enhance their inherent effector functions. All focus on the constant Fc domain …
antibodies to enhance their inherent effector functions. All focus on the constant Fc domain …
Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology
C Huang - Current opinion in biotechnology, 2009 - Elsevier
Fc fusion proteins are molecules in which the immunoglobulin Fc is fused genetically to a
protein of interest, such as an extracellular domain of a receptor, ligand, enzyme, or peptide …
protein of interest, such as an extracellular domain of a receptor, ligand, enzyme, or peptide …